Follow The Filings

CAMP CAMP4 Therapeutics

CAMP4 Therapeutics earnings company data as of 10:00 AM ET 10/23

  • 0 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS -0.21 -0.58 Miss
Rev — — —

Insider trades

Open-market buys and sales by CAMP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CAMP insider trades
  • $99K bought by 4 insiders
  • $2.5M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Kelly Gold CFO
    Buy
    $40K 10,000 shares at $3.96 New stake
    Traded Aug 31 Filed Sep 2
  2. Andrew J. Schwab Director
    Sale
    $1.6M 400,000 shares at $4.04 16% of stake
    Traded Aug 27 Filed Aug 31
  3. Andrew J. Schwab Director
    Sale
    $45 10 shares at $4.50 <0.1% of stake
    Traded Aug 24 Filed Aug 26
  4. Andrew J. Schwab Director
    Sale
    $880K 191,865 shares at $4.59 7.3% of stake
    Traded Aug 19–21 Filed Aug 21
  5. Daniel Tardiff Chief Scientific Officer
    Sale
    $8,273 1,738 shares at $4.76 100% of stake
    Traded Aug 19 Filed Aug 19
  6. Richard A Young Director
    Buy
    $27K 16,378 shares at $1.65 +9.6% to stake
    Traded Aug 3 Filed Aug 5
  7. Yuri Maricich Chief Medical Officer
    Buy
    $11K 6,551 shares at $1.65 +108% to stake
    Traded Aug 3 Filed Aug 5

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
SCHEDULE 13D/A —
SCHEDULE 13D/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
424B3
SCHEDULE 13G —
SCHEDULE 13D/A —
8-K 1.01,3.02,7.01,9.01
8-K 7.01,8.01,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —
8-K 7.01,9.01
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.